Loading...

Tzu-Yin Lin

Title(s)Assistant Researcher, Hematology and Oncology
SchoolUniversity of California, Davis
Phone916-734-3772
Emailtylin@ucdavis.edu
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Lin TY, Zhu Y, Li Y, Zhang H, Ma AH, Long Q, Keck J, Lam KS, Pan CX, Jonas BA. Daunorubicin-containing CLL1-targeting nanomicelles have anti-leukemia stem cell activity in acute myeloid leukemia. Nanomedicine. 2019 May 02; 20:102004. PMID: 31055076.
      View in: PubMed
    2. Yuan Y, He Y, Bo R, Ma Z, Wang Z, Dong L, Lin TY, Xue X, Li Y. A facile approach to fabricate self-assembled magnetic nanotheranostics for drug delivery and imaging. Nanoscale. 2018 Nov 29; 10(46):21634-21639. PMID: 30457141.
      View in: PubMed
    3. Xue X, Huang Y, Bo R, Jia B, Wu H, Yuan Y, Wang Z, Ma Z, Jing D, Xu X, Yu W, Lin TY, Li Y. Trojan Horse nanotheranostics with dual transformability and multifunctionality for highly effective cancer treatment. Nat Commun. 2018 09 07; 9(1):3653. PMID: 30194413.
      View in: PubMed
    4. Wang XS, Ding XZ, Li XC, He Y, Kong DJ, Zhang L, Hu XC, Yang JQ, Zhao MQ, Gao SG, Lin TY, Li Y. A highly integrated precision nanomedicine strategy to target esophageal squamous cell cancer molecularly and physically. Nanomedicine. 2018 10; 14(7):2103-2114. PMID: 30047470.
      View in: PubMed
    5. Wang XS, Zhang L, Li X, Kong DJ, Hu XC, Ding XZ, Yang JQ, Zhao MQ, He Y, Lam KS, Gao SG, Lin TY, Li Y. Nanoformulated paclitaxel and AZD9291 synergistically eradicate non-small-cell lung cancers in vivo. Nanomedicine (Lond). 2018 05; 13(10):1107-1120. PMID: 29874151.
      View in: PubMed
    6. Xue X, Huang Y, Wang X, Wang Z, Carney RP, Li X, Yuan Y, He Y, Lin TY, Li Y. Self-indicating, fully active pharmaceutical ingredients nanoparticles (FAPIN) for multimodal imaging guided trimodality cancer therapy. Biomaterials. 2018 04; 161:203-215. PMID: 29421556.
      View in: PubMed
    7. Long Q, Lin TY, Huang Y, Li X, Ma AH, Zhang H, Carney R, Airhart S, Lam KS, deVere White RW, Pan CX, Li Y. Image-guided photo-therapeutic nanoporphyrin synergized HSP90 inhibitor in patient-derived xenograft bladder cancer model. Nanomedicine. 2018 04; 14(3):789-799. PMID: 29317342.
      View in: PubMed
    8. Wang F, Zhang H, Ma AH, Yu W, Zimmermann M, Yang J, Hwang SH, Zhu D, Lin TY, Malfatti M, Turteltaub KW, Henderson PT, Airhart S, Hammock BD, Yuan J, de Vere White RW, Pan CX. COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin. Mol Cancer Ther. 2018 02; 17(2):474-483. PMID: 29284644.
      View in: PubMed
    9. Luo Y, Wu H, Feng C, Xiao K, Yang X, Liu Q, Lin TY, Zhang H, Walton JH, Ajena Y, Hu Y, Lam KS, Li Y. "One-Pot" Fabrication of Highly Versatile and Biocompatible Poly(vinyl alcohol)-porphyrin-based Nanotheranostics. Theranostics. 2017; 7(16):3901-3914. PMID: 29109786.
      View in: PubMed
    10. Xiao W, Suby N, Xiao K, Lin TY, Al Awwad N, Lam KS, Li Y. Extremely long tumor retention, multi-responsive boronate crosslinked micelles with superior therapeutic efficacy for ovarian cancer. J Control Release. 2017 Oct 28; 264:169-179. PMID: 28847739.
      View in: PubMed
    11. Zeng SX, Zhu Y, Ma AH, Yu W, Zhang H, Lin TY, Shi W, Tepper CG, Henderson PT, Airhart S, Guo JM, Xu CL, deVere White RW, Pan CX. The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer. Clin Cancer Res. 2017 Nov 01; 23(21):6580-6591. PMID: 28808038.
      View in: PubMed
    12. Yang X, Xue X, Luo Y, Lin TY, Zhang H, Lac D, Xiao K, He Y, Jia B, Lam KS, Li Y. Sub-100nm, long tumor retention SN-38-loaded photonic micelles for tri-modal cancer therapy. J Control Release. 2017 09 10; 261:297-306. PMID: 28700898.
      View in: PubMed
    13. Xiao K, Lin TY, Lam KS, Li Y. A facile strategy for fine-tuning the stability and drug release of stimuli-responsive cross-linked micellar nanoparticles towards precision drug delivery. Nanoscale. 2017 Jun 14; 9(23):7765-7770. PMID: 28585953.
      View in: PubMed
    14. Wang XS, Kong DJ, Lin TY, Li XC, Izumiya Y, Ding XZ, Zhang L, Hu XC, Yang JQ, Gao SG, Lam KS, Li YP. A versatile nanoplatform for synergistic combination therapy to treat human esophageal cancer. Acta Pharmacol Sin. 2017 Jun; 38(6):931-942. PMID: 28552907.
      View in: PubMed
    15. Wang SS, Zimmermann M, Zhang H, Lin TY, Malfatti M, Haack K, Turteltaub KW, Cimino GD, de Vere White R, Pan CX, Henderson PT. A diagnostic microdosing approach to investigate platinum sensitivity in non-small cell lung cancer. Int J Cancer. 2017 08 01; 141(3):604-613. PMID: 28437852.
      View in: PubMed
    16. Zimmermann M, Wang SS, Zhang H, Lin TY, Malfatti M, Haack K, Ognibene T, Yang H, Airhart S, Turteltaub KW, Cimino GD, Tepper CG, Drakaki A, Chamie K, de Vere White R, Pan CX, Henderson PT. Microdose-Induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice. Mol Cancer Ther. 2017 02; 16(2):376-387. PMID: 27903751.
      View in: PubMed
    17. Pan A, Zhang H, Li Y, Lin TY, Wang F, Lee J, Cheng M, Dall'Era M, Li T, deVere White R, Pan CX, Lam KS. Disulfide-crosslinked nanomicelles confer cancer-specific drug delivery and improve efficacy of paclitaxel in bladder cancer. Nanotechnology. 2016 Oct 21; 27(42):425103. PMID: 27640312.
      View in: PubMed
    18. Lin TY, Li Y, Liu Q, Chen JL, Zhang H, Lac D, Zhang H, Ferrara KW, Wachsmann-Hogiu S, Li T, Airhart S, deVere White R, Lam KS, Pan CX. Novel theranostic nanoporphyrins for photodynamic diagnosis and trimodal therapy for bladder cancer. Biomaterials. 2016 10; 104:339-51. PMID: 27479049.
      View in: PubMed
    19. Lin TY, Guo W, Long Q, Ma A, Liu Q, Zhang H, Huang Y, Chandrasekaran S, Pan C, Lam KS, Li Y. HSP90 Inhibitor Encapsulated Photo-Theranostic Nanoparticles for Synergistic Combination Cancer Therapy. Theranostics. 2016; 6(9):1324-35. PMID: 27375782.
      View in: PubMed
    20. Wang S, Zhang H, Scharadin TM, Zimmermann M, Hu B, Pan AW, Vinall R, Lin TY, Cimino G, Chain P, Vuyisich M, Gleasner C, Mcmurry K, Malfatti M, Turteltaub K, de Vere White R, Pan CX, Henderson PT. Molecular Dissection of Induced Platinum Resistance through Functional and Gene Expression Analysis in a Cell Culture Model of Bladder Cancer. PLoS One. 2016; 11(1):e0146256. PMID: 26799320.
      View in: PubMed
    21. Jiang S, Pan AW, Lin TY, Zhang H, Malfatti M, Turteltaub K, Henderson PT, Pan CX. Paclitaxel Enhances Carboplatin-DNA Adduct Formation and Cytotoxicity. Chem Res Toxicol. 2015 Dec 21; 28(12):2250-2. PMID: 26544157.
      View in: PubMed
    22. Gao T, Smith ZJ, Lin TY, Carrade Holt D, Lane SM, Matthews DL, Dwyre DM, Hood J, Wachsmann-Hogiu S. Smart and Fast Blood Counting of Trace Volumes of Body Fluids from Various Mammalian Species Using a Compact, Custom-Built Microscope Cytometer. Anal Chem. 2015 Dec 01; 87(23):11854-62. PMID: 26496235.
      View in: PubMed
    23. Pan CX, Zhang H, Tepper CG, Lin TY, Davis RR, Keck J, Ghosh PM, Gill P, Airhart S, Bult C, Gandara DR, Liu E, de Vere White RW. Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy. PLoS One. 2015; 10(8):e0134346. PMID: 26270481.
      View in: PubMed
    24. Lin TY, Rodriguez CO, Li Y. Nanomedicine in veterinary oncology. Vet J. 2015 Aug; 205(2):189-97. PMID: 25862394.
      View in: PubMed
    25. Tomlinson B, Lin TY, Dall'Era M, Pan CX. Nanotechnology in bladder cancer: current state of development and clinical practice. Nanomedicine (Lond). 2015; 10(7):1189-201. PMID: 25929573.
      View in: PubMed
    26. Wang F, Liu T, Yang L, Zhang G, Liu H, Yi X, Yang X, Lin TY, Qin W, Yuan J. Urethral reconstruction with tissue-engineered human amniotic scaffold in rabbit urethral injury models. Med Sci Monit. 2014 Nov 26; 20:2430-8. PMID: 25424000.
      View in: PubMed
    27. Li Y, Lin TY, Luo Y, Liu Q, Xiao W, Guo W, Lac D, Zhang H, Feng C, Wachsmann-Hogiu S, Walton JH, Cherry SR, Rowland DJ, Kukis D, Pan C, Lam KS. A smart and versatile theranostic nanomedicine platform based on nanoporphyrin. Nat Commun. 2014 Aug 26; 5:4712. PMID: 25158161.
      View in: PubMed
    28. Zhang H, Li Y, Lin TY, Xiao K, Haddad AS, Henderson PT, Jonas BA, Chen M, Xiao W, Liu R, Lam KS, Pan CX. Nanomicelle formulation modifies the pharmacokinetic profiles and cardiac toxicity of daunorubicin. Nanomedicine (Lond). 2014; 9(12):1807-20. PMID: 24628688.
      View in: PubMed
    29. Fenger JM, Bear MD, Volinia S, Lin TY, Harrington BK, London CA, Kisseberth WC. Overexpression of miR-9 in mast cells is associated with invasive behavior and spontaneous metastasis. BMC Cancer. 2014 Feb 11; 14:84. PMID: 24517413.
      View in: PubMed
    30. Lin TY, Li YP, Zhang H, Luo J, Goodwin N, Gao T, White Rde V, Lam KS, Pan CX. Tumor-targeting multifunctional micelles for imaging and chemotherapy of advanced bladder cancer. Nanomedicine (Lond). 2013 Aug; 8(8):1239-51. PMID: 23199207.
      View in: PubMed
    31. Lin TY, Zhang H, Luo J, Li Y, Gao T, Lara PN, de Vere White R, Lam KS, Pan CX. Multifunctional targeting micelle nanocarriers with both imaging and therapeutic potential for bladder cancer. Int J Nanomedicine. 2012; 7:2793-804. PMID: 22745542.
      View in: PubMed
    32. Lin TY, Zhang H, Wang S, Xie L, Li B, Rodriguez CO, de Vere White R, Pan CX. Targeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand. Mol Cancer. 2011 Jan 27; 10(1):9. PMID: 21272294.
      View in: PubMed
    33. Lin TY, Hamberg A, Pentecost R, Wellman M, Stromberg P. Mast cell tumors in a llama (Lama glama). J Vet Diagn Invest. 2010 Sep; 22(5):808-11. PMID: 20807950.
      View in: PubMed
    34. Lin TY, Hosoya K, Drost WT, Premanandan C, Wellman M. What is your diagnosis? Fine-needle aspirate of an aggressive bone lesion in a dog. Chondrosarcoma. Vet Clin Pathol. 2010 Sep; 39(3):397-8. PMID: 20561319.
      View in: PubMed
    35. Lin TY, Fenger J, Murahari S, Bear MD, Kulp SK, Wang D, Chen CS, Kisseberth WC, London CA. AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated Kit. Blood. 2010 May 27; 115(21):4217-25. PMID: 20233974.
      View in: PubMed
    36. Lin TY, London CA. Characterization and modulation of canine mast cell derived eicosanoids. Vet Immunol Immunopathol. 2010 May 15; 135(1-2):118-127. PMID: 20036014.
      View in: PubMed
    37. Lin TY, Thomas R, Tsai PC, Breen M, London CA. Generation and characterization of novel canine malignant mast cell line CL1. Vet Immunol Immunopathol. 2009 Jan 15; 127(1-2):114-24. PMID: 19054577.
      View in: PubMed
    38. Lin TY, Bear M, Du Z, Foley KP, Ying W, Barsoum J, London C. The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors. Exp Hematol. 2008 Oct; 36(10):1266-77. PMID: 18657349.
      View in: PubMed
    39. Lin TY, London CA. A functional comparison of canine and murine bone marrow derived cultured mast cells. Vet Immunol Immunopathol. 2006 Dec 15; 114(3-4):320-34. PMID: 17027994.
      View in: PubMed
    40. Lin TY, Rush LJ, London CA. Generation and characterization of bone marrow-derived cultured canine mast cells. Vet Immunol Immunopathol. 2006 Sep 15; 113(1-2):37-52. PMID: 16780961.
      View in: PubMed